SOLICITATION NOTICE
B -- Research and Development in Biotechnology
- Notice Date
- 8/28/2009
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
- ZIP Code
- 20892-7902
- Solicitation Number
- NHLBI-PB-(HL)-2009-301-DDC
- Archive Date
- 9/19/2009
- Point of Contact
- Deborah - Coulter, Phone: (301) 435-0368
- E-Mail Address
-
dc143b@nih.gov
(dc143b@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- THIS IS A NOTICE OF INTENT, NOT A REQUEST FOR A PROPOSAL. A SOLICITATION DOCUMENT WILL NOT BE ISSUED AND PROPOSALS WILL NOT BE REQUESTED. The National Heart, Lung, and Blood Institute (NHLBI) Office of Acquisition (OA) intends to negotiate and award a purchase order on a noncompetitive sole source basis to Shail Sharma,Ph.D., 144, Charak Sadan Vikaspuri (pocket E) New Delhi-110018 India, for the services as outlined below: The reference number NHLBI-PB-(HL)-2009-301-DDC. Background Information The National Heart, Lung, and Blood Institute (NHLBI) provides global leadership for a research, training, and education program to promote the prevention and treatment of heart, lung, and blood diseases and enhance the health of all individuals so that they can live longer and more fulfilling lives. The NHLBI stimulates basic discoveries about the causes of disease, enables the translation of basic discoveries into clinical practice, fosters training and mentoring of emerging scientists and physicians, and communicates research advances to the public. It creates and supports a robust, collaborative research infrastructure in partnership with private and public organizations, including academic institutions, industry, and other government agencies. The Institute collaborates with patients, families, health care professionals, scientists, professional societies, patient advocacy groups, community organizations, and the media to promote the application of research results and leverage resources to address public health needs. The NHLBI also collaborates with international organizations to help reduce the burden of heart, lung, and blood diseases worldwide. Purpose and Objectives The specific objectives for this contract are to validate the assay for morphine dependent dual regulation of adenylate cyclase. This will allow us to look for compounds which will prevent the development of tolerance and dependence on opiates while the analgesic effects of the opiates will be retained. NIH robotic system will be used. The Government plans to screen about 300,000 compounds to look for compounds that inhibit the morphine dependent increase in adenylate cyclase activity without effecting morphine dependent inhibition of adenylate cyclase. Such compounds should block addiction without inhibiting the pain killing properties of opiates. Dr. Sharma will show that morphine-dependent increases in adenylate cyclase occur under conditions that block the supersensitivity of adenylate cyclase due to morphine withdrawal. Contractor Requirements The Contractor is required to provide detailed information from data collected, organized and prepared. This will involve researching the historical records and updating the databases. Reporting Requirements and Deliverables At the end of the contract, the deliverable will be a series of documents delineating the characteristics of the research. Program Management and Control Requirements Extensive experience is required with cAMP assay, which has been used to organize the data. Inspection and Acceptance Requirements Inspection of the project will take place in the office of the Project Officer in Building 10, room, 7N315A and evaluated for acceptance whether the work is acceptable. Government Requirements The government will provide on-site laboratory space; furnish all necessary laboratory equipment, and computer facilities as needed. Period of performance: The proposed period of performance for this service is for six (6) months. The delivery point is the National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI), 10 Center Drive, Clinical Center Building 10 Room 7N315 Bethesda, Maryland 20892. The sole source determination is based on the fact that the Laboratory of Biochemical Genetics (LBG) requires the services of Dr. Shail Sharma to continue to provide guideline to research activities in this area. Due to Dr. Sharma’s knowledge and 35 years of experience working with Dr. Nierenberg of NHLBI/NIH in discovering the mechanism of action of opiates, Dr. Sharma has shown that morphine binds to opiate receptors of mouse NG10815 neuroblastoma x glioma hybrid cells that mediate inhibition of adenylate cyclase. However, during incubation with morphine for a day the cyclic AMP levels gradually increase to normal levels because the activity of adenylate cyclase gradually increases to compensate for the inhibition by morphine. The cells then appear to be tolerant to morphine and are dependent upon morphine to inhibit adenylate cyclase. Withdrawal of morphine results in about a 4 fold increase in cyclic AMP that very slowly, over a fairly long period of time returns to normal. Her services will ensure continuity of the project at LBG by imparting her extensive skills to others in the laboratory who will continue with complementary lines of research. Industry Classification (NAICS) Code is 541711, Research and Development in Biotechnology employee size standard are 500. The small business set-aside does not apply. This acquisition is being conducted under simplified acquisition procedures, and exempt from the requirements of FAR Part 6. This notice of intent is not a request for competitive proposals. Interested parties may identify their interest and capabilities in response to this requirement, within five (5) calendar days from publication date of this synopsis or by September 4, 2009 at 7:30am Eastern Standard Time. The determination by the Government not to compete the proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct future competitive procurement. Responses to this announcement, referencing synopsis number NHLBI-PB(HL)-2009-301-DDC may be submitted to the National Heart, Lung and Blood Institute, Consolidated Operations Acquisition Center, Procurement Branch, 6701 Rockledge Drive, Suite 6142, Bethesda, Maryland 20892-7902, Attention Deborah Coulter. Response may be submitted electronically to coulterd@nhlbi.nih.gov. Responses will only be accepted if dated and signed by an authorized company representative. All responsible sources may submit a quotation, which if timely received, shall be considered by the agency.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NHLBI/NHLBI-PB-(HL)-2009-301-DDC/listing.html)
- Place of Performance
- Address: NIh, Bethesda, Maryland, 20982, United States
- Zip Code: 20982
- Zip Code: 20982
- Record
- SN01932072-W 20090830/090829004743-55d2cb770962c1a29fb2594f0fdc8ee2 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |